Growth Hormone Pretreatment in Poseidon Type IV Undergoing ICSI Using Minimal Induction Protocol: A Randomized Controlled Trial

• Status: Recruiting
• Trial end date: 2022-12-30
• Target enrollment: 0
• Participant gender: Female

Summary

This study is done aiming to Assess Efficiency of Growth hormone as an adjuvant in pretreatment of Poseidon type IV group " poor responders "undergoing ICSI using minimal induction protocol

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ain Shams Maternity Hospital
• Treatments: Clomiphene; Enclomiphene; Hormones; Zuclomiphene

Criteria

Inclusion Criteria:

• -Age group between 35 to 42 years old

• AFC <5

• AMH <1.2 ng/ml

• first IVF trial

Exclusion Criteria:

• - Serious and unstable disease, such as cerebrovascular, liver, and kidney disease "will be unfit for pregnancy".

• History of malignant or border line tumors "will be unfit for pregnancy".

• Endocrine or metabolic disorder "affecting quality of oocyte so affecting results".

• Either one of the couple with chromosomal abnormalities "affecting quality of oocyte so affecting results".

• Male partner with severe oligoasthenozoospermia or with teratozoospermia"affecting quality of embryo to be transfered so affecting results".

• Any contraindications to growth hormone, pregnancy (to be ruled out and documented before GH treatment).

• female patients with causes of infertility other than poor ovarian reserve

• females suffering from congenital or acquired uterine anomalies "will affect results of implantation and pregnancy rates "

• females with focal uterine lesions anomalies "will affect results of implantation and pregnancy rates "

• BMI >30 kg/m2 "affecting quality of oocyte so affecting results".